BEIJING, July 3 (Xinhua) -- The following is a summary of published science and technology news of China.
HOME-DEVELOPED BREAST CANCER DRUG
Chinese doctors have given their patients the first sheets of prescriptions of a new, home-developed breast cancer drug.
In Beijing, Inetetamab, a targeted injection drug for metastatic HER2-positive breast cancer patients, was first prescribed in the cancer hospital of the Chinese Academy of Medical Sciences on Wednesday, 12 days after the drug was approved for clinical use.
An imported vaccine against shingles for people aged 50 and above has been available in Beijing and Shanghai from the beginning of this month.
The vaccine, Shingrix, was developed by British pharmaceutical giant GlaxoSmithKline. China's National Medical Products Administration approved it for the market in May.
It is on a list of 48 "clinically urgently needed new drugs" for fast-track approval by the administration and is currently the only recombinant shingles vaccine to hit China's market.
AI TECHS FOR URBAN MANAGEMENT
Southwest China's Chongqing Municipality has introduced a series of artificial intelligence (AI) technologies into urban management.
These AI-techs were tailored to meet the urban needs of the mountainous big city, which is a national-level pilot city of China's new generation of AI-tech development, said the report.
The series of 10 AI-techs focus on empowering Chongqing city to be "smart" in fields of city management, security systems, public legal services, parks, environmental protection, modern logistics and intelligent manufacturing.